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Abstract
Background: In high‐risk populations, allergen‐specific prophylaxis could protect
from sensitization and subsequent development of allergic disease. However, such
treatment might itself induce sensitization and allergies, thus requiring hypoaller-
genic vaccine formulations. We here characterized the preventive potential of virus‐
like nanoparticles (VNP) expressing surface‐exposed or shielded allergens.
Methods: Full‐length major mugwort pollen allergen Art v 1 was selectively tar-
geted either to the surface or to the inner side of the lipid bilayer envelope of VNP.
Upon biochemical and immunological analysis, their preventive potential was deter-
mined in a humanized mouse model of mugwort pollen allergy.
Results: Virus‐like nanoparticles expressing shielded version of Art v 1, in contrast
to those expressing surface‐exposed Art v 1, were hypoallergenic as they hardly
induced degranulation of rat basophil leukemia cells sensitized with Art v 1‐specific
mouse or human IgE. Both VNP versions induced proliferation and cytokine produc-
tion of allergen‐specific T cells in vitro. Upon intranasal application in mice, VNP
expressing surface‐exposed but not shielded allergen induced allergen‐specific anti-
bodies, including IgE. Notably, preventive treatment with VNP expressing shielded
allergen‐protected mice from subsequent sensitization with mugwort pollen extract.
Protection was associated with a Th1/Treg‐dominated cytokine response, increased
Foxp3+ Treg numbers in lungs, and reduced lung resistance when compared to mice
treated with empty particles.
Abbreviations: AHR, airway hyper-reactivity; AIT, allergen-specific immunotherapy; APC, antigen-presenting cell; BMDC, bone marrow-derived dendritic cells; DC, dendritic cells; DLS,
dynamic light scattering; DRM, detergent-resistant membrane fraction; DSM, detergent-soluble membrane fraction; Foxp3, forkhead box protein 3; FP, fusion protein; GPI,
glycosylphosphatidylinositol; i.n., intranasally; IB, immunoblot; MA, MoMLV matrix protein; MoMLV, moloney murine leukemia virus; OGP, MoMLV Gag-Pol; pTreg, peripheral Treg; RBL, rat
basophil leukemia cells; TCR, T cell receptor; Teff, T effector cells; Treg, regulatory T cell; VNP, virus-like nanoparticles.
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Conclusion: Virus‐like nanoparticles represent a novel and versatile platform for the
in vivo delivery of allergens to selectively target T cells and prevent allergies without
inducing allergic reactions or allergic sensitization.
K E YWORD S
allergy prevention, mugwort pollen allergy, Treg cells, virus‐like nanoparticles, prevention,
lung APC
1 | INTRODUCTION
More than 25% of the population in Western countries is
affected by allergies. Currently available options to manage aller-
gic diseases include allergen avoidance, symptomatic pharma-
cotherapy,1 or in severe cases application of biologics targeting
IgE or inflammatory mediators of adaptive or innate immune
cells.2-5 while the only disease‐modifying treatment available so
far is allergen‐specific immunotherapy with allergen extracts
(AIT).6,7 However, the poor quality of natural allergen extracts is
a major limitation for the development of AIT.8,9 Another chal-
lenge of AIT is that it can induce allergic side effects which can
be potentially life‐threatening.10 To overcome the disadvan-
tages of allergen extract‐based AIT, improved forms of molecu-
lar allergy vaccines are being developed and clinically
evaluated.11-15
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GRAPHICAL ABSTRACT
Allergen‐expressing VNP, which are produced in HEK 293T cells with the help of MoMLV structural proteins, are unable to stimulate allergen‐
specific B cells or sensitized effector cells (basophils, mast cells). Instead, upon i.n. application, they are being taken up by lung‐resident
CD103+ DC and alveolar macrophages, which unpack their (allergic) cargo, expand Foxp3+ Treg cells and prevent from sensitization.
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Therefore, prevention by specific approaches has become an
attractive strategy in allergy, especially in high‐risk popula-
tions.11,16,17 Today, such high‐risk populations can be reliably identi-
fied by component‐resolved molecular allergy diagnosis.18,19 The
presence and degree of sensitization against marker allergens early
on in life (ie, at 4 years of age) serve as highly significant prediction
markers for manifest disease later in life (ie, at 8 and 16 years of
age)18 and pave the way for preventive interventions such as those
based on virus‐like nanoparticles (VNP).
The principle of linking allergens to particles has been already
suggested as possible AIT strategy. This approach can be used to
reduce the allergenic activity of allergens and to enhance their
immunogenicity.20,21 Likewise, VNP may be used as allergen carri-
ers.22,23 They are noninfectious enveloped particles that are indu-
cible in mammalian cells by the expression of viral structural
proteins (ie, Gag) in the absence of viral nucleic acids or envelope
proteins. By rational incorporation22 of membrane‐bound cytoki-
nes,24-27 cytokine receptors,25 growth factors,24 fluorescent pro-
teins,22,25,27 MHC, costimulatory and also adhesion molecules,28,29
VNP have been demonstrated to sustain stimulatory but also inhi-
bitory immune responses and, as fluorescent versions, can also be
used to trace, for example, subtle receptor‐ligand interactions by
flow cytometry. However, so far, no in‐depth analysis has been
performed to investigate how the mode of linking of allergens to
VNP may affect their allergenic and tolerogenic properties and if
such a strategy can be used to foster T cell regulation. Clinically
effective AIT is associated with an increase in allergen‐specific
pTreg numbers in already allergic individuals.30-32 Similarly,
increased numbers of pTregs might also reduce the likelihood of
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(C) F IGURE 1 Scheme for the creation of allergen‐fusion proteins
(FP) and the production of surface‐expressed and shielded versions
of allergen‐expressing virus‐like nanoparticles (VNP). A, MAp15(MA::)
FPs were created by inserting Nhe I and Not I‐flanked, codon‐
optimized versions of Art v 1 or Bet v 1 into the pEAK12 expression
vector containing the Hind III and Nhe I‐tagged MoMLV matrix (MA,
p15) DNA sequence.25 Glycosylphosphatidylinositol (GPI) FPs were
generated by inserting the Hind III and Xba I‐flanked Art v 1 or Bet
v 1 sequences generated by PCR amplification into the pEAK12
vector containing the Nhe I and Not I‐flanked minimal GPI anchor
acceptor sequence of CD16b.24 B and C, Shown are VNP
production schemes for shielded (MA::allergen FP) and surface‐
exposed (allergen::GPI FP) allergens. Expression of retroviral
(MoMLV) gag-pol leads to the formation and budding of VNP from
lipid raft‐enriched regions of the plasma membrane of producer cells.
MA::allergen FP are targeted to the inner side (B) while allergen::GPI
FP become targeted to the surface of the lipid bilayer envelope (C)
of nascent VNP due to the differential posttranslational lipid
modification of their respective fusion partners
Highlights
• Full-length allergens can be specifically targeted to the
inner leaflet of MoMLV virus-like nanoparticles by fusion
to the viral matrix protein MAp15 and thus remain
shielded from IgE recognition
• Shielded allergens are hypoallergenic, do not activate,
but become engulfed by distinct subsets of antigen-pre-
senting cells and stimulate allergen-specific T cells for
proliferation and factor production
• Prophylactic application of VNP in a humanized mouse
model of mugwort allergy protects from sensitization,
elevates lung-resident Foxp3+CD4+ Treg while suppress-
ing Th2 cytokine production and thereby maintains nor-
mal lung function
KRATZER ET AL. | 3
(further) sensitization in individuals at risk to develop manifest
allergies.32-34
To study particle‐based allergen delivery, its impact on pTreg gen-
eration, and induction of allergen‐specific tolerance, we devised VNP
expressing the major mugwort pollen allergen Art v 1 either on the
VNP surface (as glycophosphatidylinositol (GPI) fusions) or shielded
by the VNP lipid envelope (as viral matrix protein (MA) fusions) and
compared the impact of their mucosal application (intranasally (i.n.))
with that of pollen extracts on subsequent allergen exposure.
Moreover, we determined the basophil activation and in vivo‐
sensitizing capabilities of allergen‐specific VNP, taking advantage of a
recently established, human‐relevant TCR/DR1 transgenic mouse
model.35 These transgenic mice express a human Art v 125-36‐specific
αβTCR and HLA‐DR1 and show hallmarks of allergic disease such as
lung inflammation, airway hyper‐responsiveness (AHR), and allergen‐
specific IgE upon natural i.n. exposure of mucosal surfaces to aque-
ous allergen extract in the absence of systemic priming or adjuvants.
In addition, we tested whether prophylactic application of allergen‐
specific VNP would mitigate allergic sensitization and AHR with aller-
gen extract and we sought to identify the responsible mechanisms.
2 | MATERIALS AND METHODS
2.1 | Production of VNP
HEK‐293T (3 × 106) cells were seeded onto 150‐mm culture dishes,
transfected the day after with 30 μg of MoMLV original gag-pol (OGP)
plasmid and 60 μg of the expression respective plasmids pEAK12::
MA::Art v 1, pEAK12:Art v 1::GPI, or empty vector. VNP‐containing
supernatants were harvested after 72 hours, filtered (0.45 μm, Milli-
pore, Billerica, MA), concentrated (Centricon Plus‐70, Merck Millipore
Ltd., Tullagreen, Ireland), and followed by concentration using a SW41
Ti rotor (1 × 105 g, 1 hour, Beckman‐Optima LE‐80K, Beckman Instru-
ments, Palo Alto, CA).26 Protein concentrations of PBS‐washed VNP
preparations were determined (Micro BCA, Thermo Fisher, Waltham,
MA) and adjusted. VNP were stored at 4°C until use for up to
4 weeks, without alteration of biological activity.
2.2 | Mice
Age‐matched, female (6‐10 weeks old), homozygous B57BL/6 mice
co‐expressing an Art v 125-36‐specific TCR and HLA‐DRA*01/‐
DRB1*01 (HLA‐DR1) heterodimers were used for experiments35
according to FELASA 2014 recommendations36 and approval by the
Ethics Committee of the Medical University of Vienna, No.BMWFW‐
66.009/0161‐WF/V/3b/2016.
2.3 | Statistical analyses
Groups with similar variance were compared using parametric tests
(Student's t test or one‐way ANOVA) followed by correction of
alpha (Tukey or Holms‐Sidak) using GraphPad 6.0 (GraphPad Soft-
ware Inc., La Jolla, CA). Otherwise, the Mann‐Whitney U test or
the Kruskal‐Wallis test was performed, followed by Dunn's multiple
comparison testing. ns, not significant; *P < 0.05; **P < 0.01;
***P < 0.001.
Further experimental details are provided in the Materials and
Methods section in this article's Appendix S1. All antibodies used
within this study are listed in Table S1.
3 | RESULTS
3.1 | Creation of cell surface‐anchored and shielded
versions of allergens on VNP
Virus‐like nanoparticles are noninfectious viral core particles, sur-
rounded by a lipid envelope derived from the host cell plasma
membrane. We here differentially associated major pollen allergens
of mugwort and birch, that is, human codon‐optimized(h)Art v 1
and hBet v 1, with VNP by fusing them N‐terminally to the
MoMLV matrix protein (MA)p1525 or C-terminally to the GPI
anchor acceptor sequence of CD16b (Figure 1A) followed by
expression analyses (Figure 1B and C)37 using the reagents listed in
Table S1. Art v 1::GPI, in contrast to MA::Art v 1, revealed signifi-
cant surface expression on 31.2 ± 11.9% of HEK‐293T transfec-
tants (Figure 2A). Notably, MA::Art v 1 showed clear‐cut
intracellular expression in the majority of transfectants upon per-
meabilization (99.6 ± 0.7) (Figure 2B). The anti‐Art v 1 mAb clone
#5 recognizes an epitope on the Art v 1 molecule, which is not
destroyed by the fixation and permeabilization procedure. There-
fore, in these stainings also the Art v 1::GPI transfectants appear
positive due to the simultaneous recognition of both surface and
intracellular pools of the GPI‐anchored Art v 1 molecule. Control
transfected HEK‐293T cells (empty pEAK12 plasmid, MA::Bet v 1
F IGURE 2 Expression of allergen‐fusion proteins in producer cells and virus‐like nanoparticles (VNP). Flow cytometry analyses of Art v 1
upon A, surface or B, intracellular staining of HEK‐293T cells transiently transfected with MA::Art v 1 or Art v 1:: glycosylphosphatidylinositol
(GPI) (solid lines), or negative control plasmid (dashed line). C and D, Shown is the mean fluorescence intensity (MFI), or E and F, the
percentage of HEK‐293T cells expressing allergen FP or transfected with control plasmids (mock and GFP), upon surface (C and E) or
intracellular (D and F) staining with the anti‐Art v 1 clone 5 mAb (mean ± SD).38 Isopycnic sucrose gradients of G, MA::Art v 1 or H, Art v 1::
GPI‐transfected HEK‐293T cell lysates immunoblotted (IB) with anti‐Art v 1, CD59, or CD147 mAb. Fractions are numbered from top 1 (5%) to
bottom 9 (40%). I, Shown are immunoblot (IB) analyses of purified allergen‐expressing VNP (20 μg/lane), empty VNP (mock), or rArt v 1 probed
with anti‐Art v 1 mAb and allergen‐expressing VNP (20 µg/lane), empty VNP (mock) or buffer control probed with p30Gag mAb. kDa indicates
molecular mass. J, Negative stain electron microscopy pictures of purified VNP. Data are representative (A, B, G‐J) or show the summary (C‐F)
of three independent experiments (except one for G) performed in triplicates. Kruskal‐Wallis test followed by Dunn's correction. ns, not
significant; ***P<0.001
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or Bet v 1::GPI) were not stained by the Art v 1 mAb (Figure 2C‐
F), while both Bet v 1 fusion proteins (FP) were recognized by the
Bet v 1‐specific mAb P639 (not shown). Transfection with GFP was
used as an independent positive control, which, however, lost its
genuine fluorescence when cells were fixed for intracellular stain-
ing40 with the anti‐Art v 1 monoclonal antibody.
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Membrane fractionation of HEK‐293T transfectants showed
that both MA::Art v 1 (Figure 2G) and Art v 1::GPI (Figure 2H),
similar to GPI‐anchored CD59 but in contrast to transmembrane
CD147, are targeted to membrane lipid rafts (fractions #2 and #3)
of gradients, which were confirmed in an independent assay41 (Fig-
ure S1A). Moreover, both Art v 1 FPs could be clearly detected in
VNP preparations derived from MA::Art v 1‐ or Art v 1::GPI‐trans-
fected HEK‐293T cells upon cotransfection with pMD.OGP (Fig-
ure 2I top panel). For SDS‐PAGE and subsequent immunoblotting,
similar amounts of VNP (20 μg/lane) were resolved as proven by
the presence of similar amounts of viral core protein Gag in the
different preparations (Figure 2I bottom panel). Both allergen FPs
had a higher molecular weight than recombinant Art v 1 due to
their fusion to the GPI anchor or MA. Neither MA::Bet v 1 VNP
nor Bet v 1::GPI VNP were recognized by the anti‐Art v 1 mAb,
although similar amounts of these VNP were loaded onto SDS‐
PAGE (Figure 2I bottom panel). Electron microscopy analyses
revealed spherical structures of approximately 100 nm resembling
VNP as described (Figure 2J).24 Dynamic light scattering deter-
mined a VNP size of 90.6 ± 22.7 nm for MA::Art v 1 VNP,
113.2 ± 16.1 nm for Art v 1::GPI VNP, and 131.3 ± 32.5 nm for
empty VNP (Figure S1B), identifying VNP as “extrafine particles.”42
The surface zeta potential of VNP revealed −13.4 ± 1.1 mV for
MA::Art v 1 VNP, −13.8 ± 1.6 mV for Art v 1::GPI VNP, and
−13.0 ± 1.7 mV for empty VNP (Figure S1C) and was indicative for
stable colloidal preparations.
3.2 | In splenocyte preparations, VNP become
preferentially engulfed by CD103+ DC and stimulate
allergen‐specific CD4+ T cells
Next, we sought to clarify whether VNP expressing allergen FPs
would activate allergen‐specific CD4+ T cells and whether this would
be preceded by their binding and uptake and/or activation of anti-
gen‐presenting cells (APC). Upon co‐incubation of splenocyte prepa-
rations with fluorescent MA::mCherry expressing VNP at 4°C,
monocytes, followed by CD103+ myeloid dendritic cells (DC), bound
VNP most efficiently. In contrast, CD103+ myeloid DC were most
actively taking up VNP at 37°C when compared to other APC sub-
sets (Figure 3A and Figure S3A). Notably, neither 24 (Figure 3B and
Figure S2A) nor 48 (Figure S2B and C) hours of co‐incubation of
MA::Art v 1 VNP, Art v 1::GPI VNP, empty VNP (10 μg/mL each), or
rArt v 1 protein (1 μg/mL) with bone marrow‐derived dendritic cells
(BMDC) of TCR/DR1 allergy mice upregulated CD40, CD80, CD86,
or MHC class II expression, when compared to medium. However,
BMDC co‐incubated with allergen‐expressing VNP secreted modest
levels of IL‐10, while inflammatory cytokines (IL‐1β, IL‐6, IL‐12, IL‐27,
or TNF‐α) were not modulated (Figure 3C and Figure S3B). Instead,
LPS (100 ng/mL) and aqueous mugwort pollen extract (100 μg/mL)
significantly upregulated all investigated activation markers and
inflammatory cytokines (Figure 3B and C and Figure S3B).
To analyze their T cell stimulatory capabilities, we incubated
splenocytes of Art v 1‐specific TCR/DR1 allergy mice with MA::Art v
1 VNP, Art v 1::GPI VNP, empty VNP (10 μg/mL), or rArt v 1
(0.5 μg/mL) and compared them to cultures supplemented with
either medium alone or PMA plus ionomycin, respectively. Of note,
both MA::Art v 1 VNP and Art v 1::GPI VNP, similar to rArt v 1,
specifically stimulated T cell proliferation (Figure 3D). In contrast,
neither empty VNP nor VNP expressing the control FPs MA::Bet v 1
or Bet v 1::GPI activated Art v 1‐specific T cells (Figure 3D). Dose‐
response determinations revealed a better stimulatory capacity of
MA::Art v 1 VNP (EC50 1.1 ± 0.2 μg/mL) compared to Art v 1::GPI
VNP (EC50 13.6 ± 7.8 μg/mL) (Figure 3E and Table S2), most likely
due to the higher concentration of Art v 1 in these VNP (Figure 2I),
which is in line with results from allergen‐specific protein determina-
tions performed with the Art v 1‐specific mAb clone #5 by ELISA. In
vitro, both Art v 1‐expressing VNP, similar to rArt v 1, but in clear
contrast to empty VNP or medium alone, stimulated the secretion of
Th1, Th2, Th17, and regulatory cytokines (Figure S4). Notably, both
MA::Art v 1 and Art v 1::GPI VNP promoted a Th1‐dominated
immune response43 with Th1/Th2‐ratios of 27.8 ± 2.9 and
35.4 ± 3.6, respectively, for IFN‐γ/IL‐4 and 9.1 ± 0.9 and 11.3 ± 7.7,
respectively, for IFN‐γ/IL‐13 (Figure S4B, E, H).
3.3 | MA::Art v 1 VNP are hypoallergenic
To study the allergenic activity of Art v 1‐expressing VNP, we
passively sensitized wild‐type rat basophil leukemia (RBL) cells or RS‐
ATL8 cells expressing the human FcεRI44 with pooled, Art v 1‐speci-
fic mouse sera or sera of five mugwort allergic individuals,
F IGURE 3 Uptake and immunostimulatory capacity of allergen‐expressing virus‐like nanoparticles (VNP). A, Binding and uptake of
fluorescent MA::mCherry VNP by the indicated splenic cell types. Open bars indicate positive cells at 4°C, filled bars show positive cells at
37°C. B, Shown is flow cytometry expression of CD40, CD80, CD86, and MHC class II (HLA DR1) on bone marrow‐derived dendritic cells
(BMDC) after co‐incubation with MA::Art v 1 VNP, Art v 1:: glycosylphosphatidylinositol (GPI) VNP, empty VNP (all at 10 μg/mL), medium
alone, rArt v 1 (1 μg/mL), aqueous mugwort pollen extract (100 μg/mL), or LPS (100 ng/mL) for 24 h. C, Shown are the cytokine levels of IL‐1β,
IL‐6, IL‐10, IL‐12, IL‐27, and TNF‐α secreted by BMDC (2 x 105/well in 200 μL) upon co‐incubation with VNP expressing MA::Art v 1, Art v 1::
GPI, empty particles, rArt v 1 (1 μg/mL), medium alone, aqueous mugwort extract (100 μg/mL), or LPS (100 ng/mL) for 24 h. D, Shown is
proliferation of splenocytes of TCR/DR1 mice incubated with MA::Art v 1 VNP, Art v 1::GPI VNP, empty VNP (10 μg/mL), rArt v 1, (0.5 μg/mL),
medium alone, or PMA/ionomycin (10−7M PMA, 120 ng/mL, respectively) for 72 h followed by a 16‐h methyl‐[3H]‐thymidine pulse (1 μCi/well).
E, Shown is dose‐dependent proliferation of splenocytes from TCR/DR1 tg mice incubated with increasing amounts of MA::Art v 1 VNP or Art
v 1::GPI VNP. Data show the summary of three independent experiments (A‐E) performed in triplicates. kcpm, kilo counts per minute; Kruskal‐
Wallis test followed by Dunn's correction (A, D, E) or one‐way ANOVA followed by Tukey's correction (B, C). ns, not significant; **P<0.01;
***P<0.001
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F IGURE 4 Shielded MA::Art v 1 expressing virus‐like nanoparticles (VNP) are hypoallergenic. A, Shown are β‐hexosaminidase release assays
of rat basophil leukemia cells (RBL)‐2H3 cells sensitized with pooled mugwort‐specific mouse sera and incubated with the indicated
concentrations of soluble rArt v 1 or VNP‐resident Art v 1, in the form of MA::Art v 1 or Art v 1:: glycosylphosphatidylinositol (GPI) VNP,
respectively. Dotted line shows the maximum degree of β‐hexosaminidase release obtained upon incubation with 100 μg of empty VNP, which
corresponds to the maximum protein concentrations of MA::Art v 1 or Art v 1::GPI VNP applied. B‐F; Shown are β‐hexosaminidase release
assays of RS‐ATL8 cells sensitized with mugwort‐specific human sera from five allergic patients and incubated with the indicated
concentrations of soluble rArt v 1 or VNP‐resident Art v 1, in the form of MA::Art v 1 or Art v 1::GPI VNP, respectively. Dotted line shows
the maximum degree of β‐hexosaminidase release obtained upon incubation with 66 μg of empty VNP, which corresponds to the maximum
protein concentrations of MA::Art v 1 or Art v 1::GPI VNP applied. Anti‐IgE mAbs were used at a fixed concentration of 10 μg/mL as FcεRI/
IgE‐specific positive controls
F IGURE 5 Significant induction of allergen‐specific immunoglobulins by virus‐like nanoparticles (VNP) expressing surface‐expressed but not
shielded allergen. A, Scheme used to expose mice and to analyze sera. Shown are Art v 1‐specific serum levels (day 56) of B, IgE, C, IgG1, and
D, IgG2a of TCR/DR1 mice, which were intranasally exposed to MA::Art v 1 or Art v 1:: glycosylphosphatidylinositol (GPI) expressing VNP,
empty particles, or aqueous mugwort extract biweekly according to A. Each symbol represents an individual mouse. E, Shows the percentage
of the indicated fluorescent cell populations in lung homogenates of mice treated with fluorescent VNP (black bars) or PBS (white bars).
Representative FACS plots of either F, alveolar macrophages and G, CD103+ dendritic cells (DCs) in lung homogenates of mice treated with
PBS (left panels) or fluorescent VNP (right panels). Data show the summary (B‐D) of 12 (except six for empty particles) treated mice per group
of two independent (except one for empty particles) experiments. E shows the summary of one of two representative experiments (n = 5 mice
per group). F and G show representative two‐parameter dot plots (n = 5 mice per group). Only significant differences are indicated in B to E.
Kruskal‐Wallis test followed by Dunn's multiple comparison. *P<0.05; **P<0.01; ***P<0.001
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respectively, and incubated them with different doses of MA::Art v 1
VNP, Art v 1::GPI VNP, empty VNP, rArt v 1, or anti‐IgE. Figure 4A‐
F and Table S3 show that MA::Art v 1 VNP, similar to empty VNP,
were hardly able to stimulate β‐hexosaminidase release from sensi-
tized RBL cells over the majority of concentrations tested. Only the
highest MA::Art v 1 VNP concentrations tested induced modest
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F IGURE 6 Preventive treatment of mice with allergen‐specific virus‐like nanoparticles (VNP). A, Scheme for preventive treatment and
challenge of mice in B‐C. B, Art v 1‐specific serum IgE levels (day 63) of TCR/DR1 mice i.n. prophylactically treated with MA::Art v 1 VNP, Art
v 1:: glycosylphosphatidylinositol (GPI) VNP, empty VNP, or PBS and challenged as indicated. C, Cytokines produced by lung homogenates of
mice (day 63) upon restimulation with aqueous mugwort pollen extract (100 μg/mL for 72 h). D, Scheme of respiratory exposure and challenge
protocol. E, Relative numbers of CD3+CD4+Foxp3+ cells in lung homogenates and F, lung resistance of mice prophylactically treated and
challenged as in D. Data show the summary (B‐C) of 13 (except four for PBS) mice per group of three (except one for PBS) independent
experiments or the summary (E) of 10 (except nine for empty VNP and PBS) mice of two independent experiments. F shows the summary of
15 (except 14 for PBS, 13 for empty particles, and 8 for Art v 1::GPI) mice of three independent experiments (except two for Art v 1::GPI).
Only significant differences are indicated. One‐way ANOVA followed by Holm's Sidak correction. *P<0.05; **P<0.01
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levels of RBL degranulation. In contrast, Art v 1::GPI VNP, similar to
rArt v 1 or anti‐IgE antibody, consistently activated RBL cells at
three of four log10‐diluted concentrations tested. Quantitative ELISA
revealed that the Art v 1 protein constitutes 17.8 ± 1.2% of the
mass of Art v 1::GPI VNP (not shown). In RBL assays, Art v 1::GPI
expressed on VNP was less active than soluble rArt v 1 suggesting
hypoallergenicity of the Art v 1::GPI variant45-47 reminiscent of pre-
viously described hypoallergenic vaccine candidates either expressed
on virus‐like particles, for example, for cat dander, or obtained upon
trimerization of the immunodominant allergen, for example, for the
major birch pollen allergen Bet v 1.20,48
3.4 | MA::Art v 1 VNP are nonimmunogenic and do
not induce Art v 1‐specific antibodies in vivo and are
taken up locally in the lung
To determine the sensitizing potential of allergen‐expressing VNP,
we i.n. exposed TCR/DR1 allergy mice to MA::Art v 1 VNP, Art v 1::
GPI VNP, empty VNP, or aqueous mugwort pollen extract four times
in biweekly intervals (Figure 5A). I.n. administration was chosen
because it directly targets the specific organs of mugwort allergy (ie,
nose, airways, and lung), and nasal sprays have proven successful,
for example, for the prevention of airborne infectious diseases (Flu-
Mist, influenza49). MA::Art v 1 VNP, as opposed to aqueous mug-
wort pollen extract, neither induced Art v 1‐specific IgE nor IgG
(Figure 5B‐D). In contrast, some of the mice exposed to Art v 1::GPI
VNP, but none of those exposed to empty VNP, developed modest,
allergen‐specific IgE, IgG1, and IgG2a levels (Figure 5B‐D). The fact
that Art v 1::GPI VNP have the principle capacity to sensitize some
of the tested mice questioned their suitability as prophylactic vac-
cine already at this stage. While empty VNP were recognized by the
MoMLV p30Gag‐specific mAb R187 in immunoblots (Figure S5A)
and ELISA (Figure S5B), no such reactivity was detectable in mouse
sera (Figure S5C‐E). In vivo uptake in lungs of fluorescently labeled
VNP was dominated by alveolar macrophages and CD103+ DCs (Fig-
ure 5E‐G). Preliminary data suggest that CD103+ DC are less potent
in taking up free allergen (not shown). Apart from the i.n., also the
s.c. route was evaluated for prophylactic VNP application. However,
under these conditions, even MA::Art v 1 VNP turned out to be sen-
sitizing as they induced allergen‐specific IgE already after three s.c.
injections. IgE levels further increased upon subsequent i.n. and
intratracheal challenges with the allergen extract (not shown).
3.5 | Preventive treatment with MA::Art v 1
expressing VNP protects from subsequent allergic
sensitization and ameliorates lung function
As MA::Art v 1 VNP were neither immunogenic nor allergenic but
clearly activated allergen‐specific CD4+ T cells in vitro (Figure 3D‐E),
we hypothesized that the in vivo application of MA::Art v 1 VNP might
inhibit subsequent sensitization with mugwort pollen extract, akin to
the mechanisms observed in peptide immunotherapy of allergy.50 To
test this, we i.n. exposed mice to MA::Art v 1 VNP, Art v 1::GPI VNP,
empty VNP or PBS twice, separated by a biweekly interval followed
by five challenges with aqueous mugwort pollen extract (Figure 6A),
known to induce fairly robust allergen‐specific IgE titers and also
allowing to monitor cytokine recall responses by lung cells. We found
that, in principle, mice exposed to MA::Art v 1 VNP during preventive
treatment did not produce allergen‐specific IgE in response to allergen
challenge (only 1 of 15 mice showed a low specific IgE titer) when
compared to mice exposed to empty VNP (7 of 13 mice produced IgE,
P = 0.01) or PBS, respectively (Figure 6B). In contrast, preventive
treatment with Art v 1::GPI VNP could not completely protect from
the induction of specific IgE in all animals (4 of 13 mice with allergen‐
specific IgE) (Figure 6B and Figure S6A and B).
Notably, restimulation of lung homogenates derived from the
four groups of mice with aqueous mugwort extract revealed a clear
decrease in Th2‐associated cytokines in mice which had been pro-
phylactically treated with MA::Art v 1 VNP compared to those
exposed to empty VNP (Figure 6C). In contrast, levels of IFN‐γ and
IL‐10 were found to be equal or even significantly elevated by pre-
ventive treatment with MA::Art v 1 VNP, indicative of a Th1/Treg‐
prone immune response (Figure 6C). Comparable data were obtained
when lung T cells were restimulated with the immunodominant Art v
123-35 peptide (Figure S6C). Spurred by these observations and cog-
nizant that Tregs are key modulators of allergen‐specific immune
responses,30-32,51 we considered that preventive treatment with
MA::Art v 1 VNP may increase the proportion of lung‐resident
CD3+CD4+Foxp3+ Tregs. Due to the different endpoints measured
in these experiments, increased sensitivity could be achieved by
shorter intervals between allergen exposures and a final intratracheal
booster with allergen.52 Investigation of lung homogenates of mice
prophylactically treated with VNP and challenged with aqueous mug-
wort pollen extract as indicated (Figure 6D) showed significantly
increased CD3+CD4+Foxp3+ Treg numbers in mice prophylactically
treated with MA::Art v 1 VNP as compared to mice treated with
empty VNP (Figure 6E and Figure S7A and B). Consistently, metha-
choline‐induced lung resistance was lowest in mice prophylactically
treated with MA::Art v 1 VNP (Figure 6F).
4 | DISCUSSION
We report the development of a new platform for the prophylactic
induction of allergen‐specific tolerance which is based on shielding of
immunodominant, full‐length allergens inside of VNP. Such allergen‐
expressing VNP are (a) hardly able to degranulate RBL cells sensitized
with allergen‐specific human or mouse IgE (ie, they are hypoallergenic),
(b) they do not induce allergen‐specific IgE or IgG in vivo (ie, they are
non-immunogenic), however, they are (c) regularly being taken up and
processed by professional APCs, and (d) activate allergen‐specific
CD4+ T cells in vitro. Importantly, we showed that MA::Art v 1 VNP,
when prophylactically (i.n.) applied, (e) increase the fraction of
CD3+CD4+Foxp3+ Tregs in lungs of allergen‐challenged mice. More-
over, (f) the increased Treg numbers correlate with the repression of
organ(lung)‐specific Th2 cytokine production and (g) AHR upon
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challenge. As allergy prevention in high‐risk populations via exposure
of the target organ to the culprit allergens is now emerging as a
novel, attractive and ethically responsible approach,16,17,53 therapeu-
tic administration of the here developed VNP was not part of this
study.
We here confirm that the VNP‐delivered allergens are critically
important for the immunoregulatory properties of VNP, as only the
preventive treatment with allergen‐expressing, but not empty VNP
or PBS, led to downregulation of IL‐2, IL‐4, IL‐5, and IL‐13 secretion
by lung‐resident T cells and increases in Foxp3+ Tregs upon rechal-
lenge in vivo. To the best of our knowledge, no allergen‐expressing
particles have been developed so far, which induce suppression of
allergen‐specific immune responses in the absence of inducing anti-
body responses. By contrast, it has been shown that they are highly
immunogenic and induce strong allergen‐specific IgG responses while
being deficient in inducing allergen‐specific T cell tolerance.20,21
Whether a tolerogenic or immunogenic effect is achieved may there-
fore depend on the type of VNP used to deliver allergens and/or on
the mode of administration. It is tempting to speculate that the T
cell‐instructing APC, which have engulfed the allergen‐expressing
VNP, might trigger specific T cells at suboptimal/differential condi-
tions known to shut‐off IL‐2 and Th2 cytokine production while
favoring a Tr1‐like cytokine environment rich in IFN‐γ and IL‐10.29,54
Alternatively, the almost complete lack of IL‐2 might also result from
consumption by the elevated numbers of Treg cells.55
How can the Treg‐inducing capability of the here created VNP
be explained? Our observation that in vivo alveolar macrophages as
well as CD103+ DC, compared to other APCs, significantly took up
VNP (Figures 3A and 5E) offers a plausible explanation. Both alveolar
macrophages, defined as CD11b−CD11c+SiglecF+ cells,56,57 and
CD11c+CD103+ DCs, are potent inducers of Foxp3+ Tregs in the
lung58,59 due to their capability to express retinaldehyde dehydroge-
nase 2, a key enzyme for the production of retinoic acid (RA) which
synergizes with TGF‐β (and IL‐10) to induce Foxp3+ Treg.57,58,60 RA
can also be induced by inhaled antigens59 and contributes to the
homeostatic, anti‐inflammatory role of lung‐resident CD103+ DCs.61
Moreover, VNP are not regarded as “dangerous” by inflammatory‐
type DCs, as no evidence for activation (Figure 3B and Figure S2A‐
C) or secretion of inflammatory cytokines (Figure 3C and Figure S3B)
was found upon coculture of allergen‐expressing or empty VNP with
BMDC. In marked contrast, LPS regularly upregulated all four activa-
tion markers on DC and induced the secretion of a whole collection
of inflammatory cytokines. This clearly indicated that VNP prepara-
tions are free of LPS and that the VNP backbone itself does not
express activating DC ligands. The latter is not entirely surprising as
HEK293 cells are used as producer cells, for example, for the pro-
duction of γ‐retroviruses applied for (experimental) gene transfer in
humans.62,63
Our MoMLV‐based VNP are clearly different from the Qβ bacte-
riophage‐based VNP described earlier.64,65 While Qβ‐based VNP
express foreign antigens/allergens exclusively as surface‐exposed
proteins/peptides on nonenveloped particles, the here described
VNP can accommodate both surface‐exposed and shielded allergens.
We here fused full‐length major allergens to the MoMLV MA p15,
which generates a post‐translationally lipid‐modified MA::allergen‐
fusion protein, robustly targeted to the inner leaflet of the lipid
bilayer envelope of budding VNP.25 This strategy yields VNP‐con-
taining major allergens, which are efficiently shielded from the envi-
ronment and prevents not only their induction of allergen‐specific
immunoglobulin responses but also their recognition by preformed
IgE bound to FcεRI and thus basophil degranulation. This is in con-
trast to Art v 1::GPI VNP and Qβ particles, which express surface‐
exposed allergen accessible (although at reduced levels) by FcεRI‐
bound IgE (Schmitz et al.20 and Figure 4A‐F) bearing the potential
risk of inducing anaphylaxis when applied to sensitized individuals
in vivo. Although Art v 1::GPI VNP clearly activate basophil degranu-
lation, their allergenic activity seems to be reduced when compared
to equimolar amounts of soluble rArt v 1 (Figure 4A‐F). The
restricted accessibility of effector cell‐bound IgE to recombinant
allergens as well as the formation of large aggregates might influence
their allergenicity as shown, for example, for Bet v 1 trimers previ-
ously.48 Significant contribution of cleaved, soluble forms of Art v 1::
GPI molecules to the RBL degranulating activity of Art v 1:GPI VNP
preparations was excluded by experiments in which either freshly
prepared and washed VNP were used for assays or the buffer solu-
tion used for resuspending and storing of Art v 1::GPI VNP was
entirely removed and exchanged by size exclusion centrifugation,
ultracentrifugation, or both, directly before performing the RBL
assays. Such experiments did not reveal differences in RBL degranu-
lation induced by the differently prepared/purified VNP, indicating
that Art v 1::GPI associated with the VNP surface is stable and the
only relevant stimulating principle. Apart from that, the here
described VNP also seem to be poor B cell antigens as neither pro-
phylactic treatment with allergen‐expressing nor empty VNP led to
significant antibody responses against VNP constituents themselves
as shown by Western blotting (Figure S5A) and ELISA (Figure S5B‐
E). In addition, no antibody responses directed against the MA‐ or
GPI‐fusion partners used to attach Art v 1 to the inner or outer side
of VNP could be observed (not shown). Nevertheless, as Art v 1::GPI
VNP had the principle capacity to sensitize at least some of the pro-
phylactically treated mice, they are considered inappropriate candi-
dates for a prophylactic vaccine formulation.
Why empty VNP ameliorated lung resistance to a certain degree
remains to be elucidated in future experiments. One possibility enter-
tained in the past for the beneficial impacts on allergic symptoms of
CpG‐rich VNP lacking allergen was their engagement of pattern recog-
nition receptors on both innate and adaptive immune cells.66 So far,
we did not find evidence that VNP (empty or allergen‐specific) would
activate DC (Figure 3B and Figure S2A‐C); however, future studies will
address that question in greater detail.
What could be the advantage of applying allergen‐expressing
VNP over artificial liposomes containing recombinant allergens for
vaccination purposes? VNP copackage complement regulatory pro-
teins, for example, CD55 and CD59 “borrowed” from HEK‐293T
cells (Figure 2G and H), possibly preventing immediate complement
attack and thus premature degradation upon in vivo application.
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Moreover, VNP can easily accommodate other lipid‐modified,
immunoregulatory molecules of choice, for example, cytokines and
growth factors impacting on DC activation and differentiation or
shaping Teff cell programs.
29,67 Moreover, oligo‐ or poly‐valent VNP
could be generated, for example, by coexpression of several MA::al-
lergen FPs or by concatenation of two or more allergens with MA.
During VNP generation, the processes of allergen expression and
envelopment are separately regulated, making the introduced aller-
gen sequences amenable to facile manipulation (eg, display hypoal-
lergens or altered peptide ligands68) and allowing for the
introduction of further bioactive molecules (eg, regulatory proteins
and/or (ribo)nucleic acids69).
In summary, allergen‐specific VNP expressing shielded cargo are
novel formulations with high potential for allergen‐specific preven-
tion of IgE sensitization and may be used as prophylactic allergy
vaccines.
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